Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms

JAMA Intern Med. 2022 Dec 1;182(12):1321-1323. doi: 10.1001/jamainternmed.2022.4928.

Authors

Justin M Dubin¹, Erin Jesse², Richard J Fantus³, Nelson E Bennett¹, Robert E Brannigan¹, Nannan Thirumavalavan², Joshua A Halpern¹

Affiliations

¹ Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Urology Institute, University Hospitals, Case Western Reserve University School of Medicine, Cleveland, Ohio.
³ Department of Surgery, Northshore University Health System, Evanston, Illinois.

No abstract available

Plain language summary

This cross-sectional study examines whether direct-to-consumer platforms provide guideline-concordant care regarding testosterone therapy.

MeSH terms

Guideline Adherence*
Humans
Length of Stay
Testosterone* / therapeutic use

Substances

Testosterone